Mohiuddin M, Marks G, Bannon J
Department of Radiation Medicine, University of Kentucky, Lexington 40536.
Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):845-9. doi: 10.1016/0360-3016(94)90359-x.
To assess the efficacy of high-dose preoperative radiation and full thickness local excision as an option for the management of selected distal rectal cancers.
Forty-eight patients with invasive distal rectal cancer have been treated with high-dose preoperative radiation (45-55 GY at 180 cGy/fx) followed 6 to 8 weeks later by full thickness local excision. Three groups of patients are included in this study. Group 1 (N = 15) Medically Compromised: patients with rectal cancers Stages T3 or > 3 cm in size and significant cardiorespiratory disease that precluded radical surgery. Group 2 (N = 18) Elective: patients suitable for local treatment by standard criteria (Stages < T2 and < 3 cm in size), and group 3 (N = 15) Staged: patients with Stages T3 or > 3 cm in size that postradiation were downstaged and met the criteria as in group 2. One patient in group 3 was found to be pathologically T3 following full thickness local excision and was converted to an abdominoperineal resection. Follow-up ranges from 6-96 months with a median of 40 months.
The overall 5-year actuarial survival for the whole group is 83.5% and local recurrence is 10%. The 5-year survival is 74%, 92%, and 88% for Groups 1, 2, and 3 and 90%, 89%, and 50% for postradiation pathologic stages T0/T1, T2, and T3, respectively. Local recurrence rate by treatment groups are 20%, 11%, and 0% for groups 1, 2, and 3 and 11%, 0%, and 67% for postradiation Stages T0/T1, T2, and T3, respectively. Surgical complications, primarily wound healing, were observed in five patients (10%). Four patients required a subsequent colostomy (three for recurrence and one for a rectovaginal fistula). Sphincter function as measured by Parks criteria was good/excellent in 88% of patients.
High-dose preoperative radiation and full thickness local excision appear to be a promising new option for the management of selected patients with invasive distal rectal cancers. Selected patients with Stage T3 cancers that as a result of preoperative radiation are downstaged and met the criteria for primary local therapy (T2 or less) appear to have an excellent survival with retained normal sphincter function following full thickness local excision.
评估大剂量术前放疗联合全层局部切除作为特定远端直肠癌治疗方案的疗效。
48例浸润性远端直肠癌患者接受了大剂量术前放疗(45 - 55 Gy,每次180 cGy),6至8周后进行全层局部切除。本研究纳入三组患者。第1组(N = 15):医学上存在并发症的患者,患有T3期或肿瘤大小> 3 cm的直肠癌,且伴有严重心肺疾病,无法进行根治性手术。第2组(N = 18):选择性患者,符合标准(T2期以下且肿瘤大小< 3 cm)适合局部治疗。第3组(N = 15):分期患者,患有T3期或肿瘤大小> 3 cm,放疗后分期降低并符合第2组标准。第3组中有1例患者在全层局部切除后病理检查为T3期,随后改为腹会阴联合切除术。随访时间为6 - 96个月,中位时间为40个月。
全组5年实际生存率为83.5%,局部复发率为10%。第1、2、3组的5年生存率分别为74%、92%和88%,放疗后病理分期T0/T1、T2、T3的5年生存率分别为90%、89%和50%。治疗组的局部复发率第1、2、3组分别为20%、11%和0%,放疗后分期T0/T1、T2、T3的局部复发率分别为11%、0%和67%。观察到5例患者(10%)出现手术并发症,主要是伤口愈合问题。4例患者随后需要进行结肠造口术(3例因复发,1例因直肠阴道瘘)。根据Parks标准测量,88%的患者括约肌功能良好/优秀。
大剂量术前放疗联合全层局部切除似乎是治疗特定浸润性远端直肠癌患者的一种有前景的新选择。因术前放疗分期降低并符合原发局部治疗标准(T2期及以下)的特定T3期癌症患者,在全层局部切除后似乎具有良好的生存率且保留了正常的括约肌功能。